ClinicalTrials.gg
RecruitingNCT07620691Updated Jun 2, 2026

N95 Masks for Lung Health While Golfing During Wildfire Season

An interventional study of N95 mask in Bronchial Asthma, sponsored by University of Saskatchewan. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by University of Saskatchewan · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Lung health is negatively affected during wildfire season by increased smoke pollution. Wearing N95 masks protects lung health in the short-term. The purpose of our study is to assess whether wearing of N95 facemasks on days with moderate to high air pollution in people who go outside to golf on a regular basis (two or more times per week) for two months during the wildfire season projects lung health.

Read the detailed description

Wildfire smoke negatively affects lung health. Across North American, millions of people are exposed to wildfire smoke most summers. The purpose of our study is to determine whether people who golf regularly (two or more times per week) can use N95 masks to protect their lungs from wildfire smoke. Forty regular golfers will be randomized to receive N95 masks or not to receive masks. All participants will be told to follow guidelines for outdoor activity based on Air Quality Health Index readings. Those randomized to wear N95 facemasks will be asked to wear these on days they golf where Air Quality Health Index indicates moderate risk or higher. The main outcome is compliance with wearing the N95 mask. Secondary outcomes include changes in lung function, blood pressure, and respiratory symptoms over two months.

02

Conditions studied

  • Bronchial Asthma

Browse trials for

03

In context

Asthma

4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.

This study's planned enrollment of 40 is below the median of 78 across 3,341 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

University of Saskatchewan is the lead sponsor of 243 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Golf on a regular basis (two or more times per week)

Exclusion criteria

Exclusion Criteria:

  • Smoker
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    N95 mask

    N95 masks will be worn outdoors when Air Quality Health Index indicates moderate risk or higher (4 or higher)

    Device: N95 mask

  • No intervention
    No N95 mask

    No N95 masks will be provided to participants

Interventions

  • DeviceN95 mask

    N95 mask to be worn outside when golfing when Air Quality Health Index reading indicates moderate risk or higher

06

What researchers measure

Primary outcomes

  1. Change in compliance with wearing of N95 masks (number of times divided by days with moderate or higher air pollution)

    compliance with wearing the N95 masks

    Time frame: 8 weeks

Secondary outcomes

  1. Change in forced expiratory volume in one second (L)

    Force expiratory volume in one second measured with spirometry

    Time frame: 8 weeks

  2. Change in forced vital capacity (mL)

    Forced vital capacity measured by spirometry

    Time frame: 8 weeks

  3. Change in forced expiratory flow at 25% to 75% of vital capacity (mL)

    forced expiratory flow at 25% to 75% of vital capacity measured by spirometry

    Time frame: 8 weeks

  4. Change in respiratory symptoms (score out of 12)

    Respiratory symptoms determined by the Dyspnoea-12 questionnaire

    Time frame: 8 weeks

  5. Change in systolic blood pressure (mmHg)

    Systolic blood pressure measured by an automatic sphygmomanometer

    Time frame: 8 weeks

  6. Change in diastolic blood pressure (mmHg)

    Diastolic blood pressure measured by an automatic sphygmomanometer

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07620691
Responsible party
Phil Chilibeck (Professor, University of Saskatchewan) — Principal investigator
First posted
Jun 2, 2026
Start date
May 26, 2026
Primary completion
Sep 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 2, 2026

Study contacts

Philip Chilibeck, PhD
Contact
phil.chilibeck@usask.ca
3062303849
Philip Chilibeck, PhD
principal investigator · University of Saskatchewan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion